Table 3.

Comparison of clinical and biochemical characteristics of our patients with previously reported cases who have the same mutations

Mutation Alleles	Patient	Sex	Age at Onset, y	Age at Diagnosis, y	BP, mm Hg	Serum K, mmol/L	PRA, ng/mL/h	PAC, ng/dL	Triamterene Treatment
									BP, mm Hg	Serum K, mmol/L
p.Arg566Ter	C	F	14	32	190/130	2.5	↓	↓	120/70	4.0
	D	M	17	18	200/120	2.9	↓	↓	125/70	4.0
	Wang3	M	13	–	180/110	3.2	↓	↓	130/70	4.0
	Gong4	M	15	–	200/140	2.8	↓	↓	Controllable	Normal range
p.Arg564Ter	E	F	18	24	180/140	3.0	↓	↓	125/85	4.0
	Melander5	F	–	60	160/80	3.8			–	–
		F	–	20	185/120	3.4	↓	–	–	–
		F	–	30	190/115	3.3	↓	↓	–	–
		M	–	18	140/90	3.7	↓	↓	–	–
		F	–	16	115/80	3.8	–	↓	–	–
		M	–	27	135/80	4.0	–	–	–	–
p.Pro617Ser	H	F	15	20	190/120	2.9	↓	↓	135/75	3.8
	Inoue6	M	–	28	142/92	3.4	↓	↓	Effective	Effective
		M	–	27	174/120	3.5	↓	↓	Effective	Effective
		M	–	20	160/100	3.3	↓	↓	Effective	Effective
p.Pro618Leu	J	M	14	26	185/110	3.0	↓	↓	125/80	4.0
	Hansson7	–	15	41	180/140	2.8	↓	↓	122/70	–
		–	1.5	11	140/95	2.9	↓	↓	115/63	–
		–	1.5	13	130/90	3.3	↓	↓	–	–
p.Asn619Gln	I	M	15	–	200/110	3.0	↓	↓	130/80	3.5
	Yang8	M	17	–	160/100	3.1	↓	↓	110/80	4.1

Abbreviations: F, female; K, potassium; M, male; PAC: plasma aldosterone concentration (normal range: 6.5–29.5 ng/dL); PRA, plasma renin activity (normal range: 0.93–6.56 ng/mL/h); ↓, low plasma renin activity or low plasma aldosterone concentration; –, unavailable.